RE:Zacks initiates research coverage with an outperformThanks for posting.....good things to come....
"We are initiating Coverage of iCo Therapeutics Inc. with an
Outperform rating and $0.90 price target.
Sum-of-parts modeling calculates that iCo Therapeutics
shares are meaningful undervalued at today’s market value of
only $30 million on a basic share count basis. We find this
bafflingly low. Our analysis finds that the shares should be
valued more in the $100-105 million range, or around $0.90
per share on a fully-diluted basis based on a 50% probability
of success of the iDEAL trial. This represents tremendous
upside to investors at today’s price of only $0.38 per share."